Wall Street Increases Loss Estimates for Exact Sciences Following Details of Clinical Trial Plans | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – One day after Exact Sciences announced its second-quarter earnings and provided details about the clinical trial for its colorectal cancer screening test, Wall Street reacted in mixed fashion, as several analysts increased their loss-per-share estimates for 2011 and 2012, and one downgraded Exact Sciences' stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.